title: Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.
abstract: The current consensus guidelines were developed to standardize the clinical approach to the management of neutropenic fever in adult cancer patients throughout Australian treating centres. The three areas of clinical practice covered by the guidelines, the process for developing consensus opinion, and the system used to grade the evidence and relative strength of recommendations are described. The health economics implications of establishing clinical guidance are also discussed.
authors.affiliation: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: S
authors.initials: S
authors.lastname: Lingaratnam
authors.forename: M A
authors.initials: MA
authors.lastname: Slavin
authors.forename: B
authors.initials: B
authors.lastname: Koczwara
authors.forename: J F
authors.initials: JF
authors.lastname: Seymour
authors.forename: J
authors.initials: J
authors.lastname: Szer
authors.forename: C
authors.initials: C
authors.lastname: Underhill
authors.forename: M
authors.initials: M
authors.lastname: Prince
authors.forename: L
authors.initials: L
authors.lastname: Mileshkin
authors.forename: M
authors.initials: M
authors.lastname: O'Reilly
authors.forename: S W
authors.initials: SW
authors.lastname: Kirsa
authors.forename: C A
authors.initials: CA
authors.lastname: Bennett
authors.forename: I D
authors.initials: ID
authors.lastname: Davis
authors.forename: O
authors.initials: O
authors.lastname: Morrissey
authors.forename: K A
authors.initials: KA
authors.lastname: Thursky
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001315:Australia; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002173:Cancer Care Facilities / Q000592:standards; D003245:Consensus Statements as Topic; D003362:Cost-Benefit Analysis; D003625:Data Collection; D005334:Fever / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D016867:Immunocompromised Host; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000191:economics; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications* / Q000191:economics; D010818:Practice Patterns, Physicians'; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor